thinkpool

Interleukin 1, Pipeline Review, H1 2020 - Devonian Health Group Inc, Link Health Group, Novartis AG & XBiotech Inc - ResearchAndMarkets.com




January 31, 2020 10:44 AM Eastern Standard Time <meta content="2020-01-31T15:44:00Z" itemprop="datePublished">


DUBLIN--( BUSINESS WIRE)--The "Interleukin 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.


“Interleukin 1 - Pipeline Review, H1 2020”
Tweet this
Summary

Interleukin 1 (IL1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Interleukin 1 (IL1) - Pipeline Review, H1 2020, outlays comprehensive information on the Interleukin 1 (IL1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.  Interleukin 1 (IL1) - Interleukin-1 is a cytokine which plays an important role regulation of immune and inflammatory responses. It helps leukocytes pass through blood vessel walls to sites of infection and causes fever by affecting areas of the brain that control body temperature. There are two forms of interleukin-1, alpha and beta. IL-1 stimulates thymocyte proliferation by inducing IL-2 release, B-cell maturation and proliferation, and fibroblast growth factor activity. The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 6, 2, 10 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.




Furthermore, this report also reviews key players involved in Interleukin 1 (IL1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope
The report provides a snapshot of the global therapeutic landscape for Interleukin 1 (IL1)
The report reviews Interleukin 1 (IL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Interleukin 1 (IL1) targeted therapeutics and enlists all their major and minor projects
The report assesses Interleukin 1 (IL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Interleukin 1 (IL1) targeted therapeutics

Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Interleukin 1 (IL1)
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Interleukin 1 (IL1) development landscape
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered: Introduction
Report Coverage
Interleukin 1 (IL1) - Overview
Interleukin 1 (IL1) - Therapeutics Development  Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Interleukin 1 (IL1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 (IL1) - Companies Involved in Therapeutics Development
3SBio Inc
Bioiberica SAU
Devonian Health Group Inc
Johnson & Johnson
Komipharm International Co Ltd 

​

​Link Health Group
Mabpharm Ltd
Moderna Therapeutics Inc
Novartis AG
Omnitura Therapeutics Inc
Opsona Therapeutics Ltd
Peptinov SAS
R Pharm
Regeneron Pharmaceuticals Inc
Spherium Biomed SL
Swedish Orphan Biovitrum AB
Therapicon Srl
TWi Biotechnology Inc
XBiotech Inc
Interleukin 1 (IL1) - Drug Profiles
AC-203 - Drug Profile
bermekimab - Drug Profile
Interleukin 1 (IL1) - Dormant Products
Interleukin 1 (IL1) - Discontinued Products
Interleukin 1 (IL1) - Product Development Milestones
Featured News & Press Releases
Appendix

Companies Mentioned
3SBio Inc
Bioiberica SAU
Devonian Health Group Inc 

Johnson & Johnson
Komipharm International Co Ltd
Link Health Group

Mabpharm Ltd
Moderna Therapeutics Inc
Novartis AG
Omnitura Therapeutics Inc
Opsona Therapeutics Ltd
Peptinov SAS
R Pharm
Regeneron Pharmaceuticals Inc
Spherium Biomed SL
Swedish Orphan Biovitrum AB
Therapicon Srl
TWi Biotechnology Inc
XBiotech Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tc5d7s






Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900 

​